Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion type Assertion NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_head.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion description "[In the squamous cell carcinoma (SCC) cell lines SCC9 and SCC25, lovastatin treatment (1-25 �M, 24 hrs) induced LKB1 and AMPK activation similar to metformin (1-10 mM, 24 hrs), a known inducer of this pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_provenance.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion evidence source_evidence_literature NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_provenance.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion SIO_000772 23029387 NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_provenance.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion wasDerivedFrom befree-20140225 NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_provenance.
- NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_assertion wasGeneratedBy ECO_0000203 NP359515.RAnKPVO-QlsLkU7qxQkCNYaP1P-XcDr2QVsdz_F-sEDH4130_provenance.